Fisher & Paykel Healthcare is a long-term play

Fisher & Paykel Healthcare is a long-term play
Chief executive Lewis Gradon (Image: Fisher & Paykel Healthcare)
Rebecca Howard
Fisher & Paykel Healthcare will benefit from the fact that its nasal high-flow therapy machine became the frontline choice for covid-19, but it won’t happen overnight. “The only real thing that covid-19 changed is that customers have a lot of the hardware,” said chief executive Lewis Gradon. Revenue in the year to March 31, 2019, was just over $1 billion. By the 2021 financial year, it had jumped to nearly $2b as the company moved swiftly to supply hospitals around the world with nasal high-flow therapy mach...

More Markets

NZX falls as Synlait and Mainfreight take hits
Markets Market Close

NZX falls as Synlait and Mainfreight take hits

Market reacts strongly to news of "challenges" at Synlait's Dunsandel plant.

Tom Raynel 30 Jul 2025
'Slow and disappointing' start to the year for Mainfreight
Markets

'Slow and disappointing' start to the year for Mainfreight

The freight and logistics firm said profits were down across its three main divisions.

Staff reporters 30 Jul 2025
Ryman toils to rebuild shareholder confidence
Property

Ryman toils to rebuild shareholder confidence

"When is the total board going to resign?" asked one shareholder.

Gregor Thompson 30 Jul 2025
Synlait shares slump 11% even as outlook brightens
Primary Sector

Synlait shares slump 11% even as outlook brightens

The market is disappointed about manufacturing challenges. 

Rebecca Howard 30 Jul 2025